Targeting the BH3-interacting domain death agonist to develop mechanistically unique antidepressants

Area of Science:

• Neuroscience
• Molecular Biology
• Pharmacology

Background:

• The B-cell lymphoma-2 (Bcl-2) protein family, including BH3-interacting domain death agonist (Bid), plays a crucial role in cellular resilience and neuronal plasticity.
• Reduced Bcl-2 levels in specific brain regions are linked to mood disorder pathophysiology, while antidepressants can increase these levels.
• Bid is a pro-apoptotic protein implicated in cellular stress responses relevant to mood disorders.

Purpose of the Study:

• To investigate the therapeutic potential of inhibiting Bid in rodent models of depression.
• To evaluate the effects of Bid antagonists (BI-11A7, BI-2A7) and a selective serotonin reuptake inhibitor (citalopram) on depression-related behaviors.
• To explore the impact of Bid inhibition on apoptosis-inducing factor (AIF) activation in the context of learned helplessness.

Main Methods:

• Pharmacological inhibition of Bid using antagonists BI-11A7 and BI-2A7 in mice.
• Utilized established depression models: forced swim test (FST), tail suspension test (TST), and learned helplessness (LH) paradigm.
• Assessed reward-seeking behavior using the female urine sniffing test (FUST) and measured AIF activation.

Main Results:

• Both citalopram and the Bid antagonist BI-11A7 significantly reduced immobility in the FST and TST.
• These agents also attenuated escape latencies in the LH paradigm and improved sniffing behavior in the FUST.
• Learned helplessness induction increased AIF activation, which was attenuated by chronic BI-11A7 treatment.

Conclusions:

• Functional perturbation of apoptotic proteins like Bid represents a potential therapeutic strategy for mood disorders.
• Enhancing Bcl-2 function offers an alternative avenue for developing novel depression therapeutics.
• Targeting apoptotic pathways provides a promising direction for future mood disorder treatments.